Recursion Pharmaceuticals today announced the award of a $546,000grant from the Bill & Melinda Gates Foundation to apply Recursion’s AI-enabled technology to the discovery of novel drugs with the ability to treat malaria. “We are proud to contribute to the foundation’s goal of a world free of malaria,” said Chris Gibson, Ph.D., CEO of Recursion Pharmaceuticals. “Like…